Immune tolerance

Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT

Retrieved on: 
Tuesday, April 9, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Disease, Allo, Infection, Incidence, Patient, Immune tolerance, Gastrointestinal tract, GI, David Berry (inventor), Mortality, Bacteria, HSCT, Bloodstream infections, Graft-versus-host disease, Therapy, Chronic liver disease, Safety, Immunodeficiency, Data, Pharmaceutical industry

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that enrollment is complete in the placebo-controlled Cohort 2 of its Phase 1b trial of SER-155 in patients who received Allogeneic Hematopoietic Stem Cell Transplantation (Allo HSCT).

Key Points: 
  • Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that enrollment is complete in the placebo-controlled Cohort 2 of its Phase 1b trial of SER-155 in patients who received Allogeneic Hematopoietic Stem Cell Transplantation (Allo HSCT).
  • Infections are a leading cause of mortality and morbidity in this immunocompromised patient population.
  • Our pending clinical results could validate the promise of microbiome therapeutics to prevent poor outcomes associated with pathogens in the GI tract.
  • Study Cohort 2, which includes 45 participants, incorporates a randomized, double-blinded placebo-controlled 1:1 design to further evaluate safety and engraftment, as well as clinical outcomes.

Akston Biosciences' AKS-107 Study Published in Frontiers in Immunology, Displaying Ambifect® Platform’s Versatility

Retrieved on: 
Monday, March 11, 2024
Biotechnology, Manufacturing, Diabetes, Health, Pharmaceutical, Research, Other Manufacturing, Infectious Diseases, Science, Veterinary, Clinical Trials, MERS, NOD, Atopic dermatitis, Insulin, Immune tolerance, CGMP, Epitope, Mouse, Immunoglobulin G, Chronic pain, Protein, Infection, Vaccination, Immune system, Nerve growth factor, Notifiable disease, Dengue fever, Vaccine

The study demonstrated AKS-107's potential to target and delete insulin-specific B cells, which are implicated in the development of Type 1 Diabetes (T1D).

Key Points: 
  • The study demonstrated AKS-107's potential to target and delete insulin-specific B cells, which are implicated in the development of Type 1 Diabetes (T1D).
  • AKS-107 is a human IgG1 Fc-fusion protein engineered to retain conformational insulin epitopes that bind to B cell receptors while preventing binding to the insulin metabolic receptor.
  • Regarding its Animal Health applications, Akston is partnered with Dechra Pharmaceuticals PLC to commercialize canine and feline ultra-long insulins.
  • Akston Biosciences Corporation is dedicated to accelerating the next revolution in Animal Health by inventing, developing, and manufacturing breakthrough protein therapeutics for veterinary use.

Press Release: Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors

Retrieved on: 
Thursday, February 22, 2024
Senior, Audit, Compass Group, Immunology, Clotilde Delbos, Emlyon Business School, Henley Business School, Nomination, Duke, Axa, Bucknell University, Interim, Specialization, Therapy, Biology, Committee, Childhood arthritis, RCI Banque, Pechiney, Pandion, GSK plc, PwC, Division, Lonrho, Gilead Sciences, Merlin, Corporate responsibility, Audit committee, Business administration, Duke University, Immune tolerance, Science, Annual, Management

Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors

Key Points: 
  • Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors
    Paris, February 22, 2024.
  • The Chairman warmly thanked them for their valued contribution to the Board of Directors and the specialized committees to which they belonged during their terms in office.
  • In 2016, Clotilde Delbos was appointed Group Chief Financial Officer and Chairman of Board of Directors of RCI Banque.
  • “The arrivals of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy will strengthen the Board of Directors’ expertise in finance and science, notably in the field of immunology.

Groundbreaking Study Demonstrates 20-Year Remission in Pemphigus Vulgaris Patients Using IVIg Therapy

Retrieved on: 
Wednesday, January 31, 2024
Ahmad, Research, Science, Pemphigus vulgaris, National academy, Patient, Avicenna, Immune tolerance, Doctor of Science, MPA, PNAS, FRCP, Immunoglobulin therapy, DDF, Admiration

Researchers from Tufts University School of Medicine (Boston, MA) and Sorbonne Université (Paris, France) have demonstrated a remarkable 20-year clinical and serological remission in patients using a defined protocol of intravenous immunoglobulin (IVIg) therapy.

Key Points: 
  • Researchers from Tufts University School of Medicine (Boston, MA) and Sorbonne Université (Paris, France) have demonstrated a remarkable 20-year clinical and serological remission in patients using a defined protocol of intravenous immunoglobulin (IVIg) therapy.
  • Twenty-one patients with confirmed PV received IVIg therapy according to a specific protocol.
  • This long-term remission suggests that IVIg may help restore immune balance and tolerance in PV patients.
  • The pioneering research, offering sustained remission for pemphigus vulgaris patients, highlights the considerable potential of IVIg therapy.

COUR Pharmaceuticals Secures $105 Million in Series A Financing Co-Led by Lumira Ventures and Alpha Wave Ventures

Retrieved on: 
Tuesday, January 30, 2024
JDRF, Primary biliary cholangitis, Bristol Myers Squibb, Immune system, Coeliac disease, Patient, Immune tolerance, T1D, Disease, Myasthenia gravis, Takeda Pharmaceutical Company, Vaccine

The investment was co-led by Lumira Ventures and Alpha Wave Ventures, with participation from Roche Venture Fund, Pfizer (as part of the Pfizer Breakthrough Growth Initiative), Bristol Myers Squibb, Angelini Ventures, and the JDRF T1D Fund.

Key Points: 
  • The investment was co-led by Lumira Ventures and Alpha Wave Ventures, with participation from Roche Venture Fund, Pfizer (as part of the Pfizer Breakthrough Growth Initiative), Bristol Myers Squibb, Angelini Ventures, and the JDRF T1D Fund.
  • In connection with the financing, Benjamin “Beni” Rovinski, Ph.D., Managing Director of Lumira Ventures, and Simon Greenwood, Senior Investment Director of Roche Venture Fund, will join the COUR Board of Directors.
  • We believe COUR's proprietary and strongly differentiated platform is a versatile and first-in-class approach to meet this critical medical need.
  • We are dedicated to collaborating with COUR and its partners to help advance these potentially cutting-edge treatments for immune-related diseases.”

Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida

Retrieved on: 
Tuesday, January 30, 2024
Partnership, University, Neurodegenerative disease, Science, Research, Immune system, Alpha-synuclein, Translational research, Ageing, Conditional sentence, Faculty, Immune tolerance, Antibody, Biomedical Research, UF, Brain, Protein, Vaccine, Disease, Health, Student

The research, funded by a grant from the state of Florida, aims to further the development of Vaxxinity’s active immunotherapies to prevent and mitigate neurodegenerative diseases, having the potential to change the future of treatment by offering people an affordable and accessible therapeutic option.

Key Points: 
  • The research, funded by a grant from the state of Florida, aims to further the development of Vaxxinity’s active immunotherapies to prevent and mitigate neurodegenerative diseases, having the potential to change the future of treatment by offering people an affordable and accessible therapeutic option.
  • “Our collaboration with the University of Florida will support the continued development of vaccines for neurodegenerative diseases affecting millions of people worldwide,” said Mei Mei Hu, CEO of Vaxxinity.
  • This project will complement preclinical work conducted at Vaxxinity, which has already shown immunogenicity, target engagement, and efficacy in animal models of multiple neurodegenerative diseases including Alzheimer’s and Parkinson’s .
  • The Company will provide materials, including candidates derived from its platform and antibodies generated by active immunotherapy treatment, to support the collaborative research at UF.

Vaxxinity Announces Collaboration on Space Medicine Research with University of Central Florida

Retrieved on: 
Thursday, January 18, 2024
The College of Medicine, Notifiable disease, UCF, University, Immune tolerance, Research, State, Longevity, Antibody, College, Central Florida, Ageing, Immune system

CAPE CANAVERAL, Fla., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of medicines, today announced a collaboration with the University of Central Florida (UCF) to advance space medicine research.

Key Points: 
  • CAPE CANAVERAL, Fla., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of medicines, today announced a collaboration with the University of Central Florida (UCF) to advance space medicine research.
  • “If humanity is to become a spacefaring species, solving fundamental problems related to space travel and living are table-stakes.
  • The company will provide materials including candidates derived from its platform to support the collaborative research at UCF.
  • “UCF was born as a university to support the space program, and the College of Medicine is continuing that mission, working to bring back to Earth the secrets that space medicine research can reveal,” said Dr. Deborah German, vice president for health affairs and dean of UCF’s College of Medicine.

Vaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, November 8, 2023
Research, The Michael J. Fox Foundation, AD, PD, Immune tolerance, Food, Hypercholesterolemia, MJFF, Fast track (FDA), CSF, Pathology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Civil Service (United Kingdom), Traffic barrier, BBB, LDL, COVID-19, Antibody, Partnership, Comparison, PCSK9, Brain, Investment, Patient, Rare-earth element, Vaccine, Pharmaceutical industry, Cryptocurrency

CAPE CANAVERAL, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of medicines, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.

Key Points: 
  • CAPE CANAVERAL, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of medicines, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.
  • This quarter, we have demonstrated proof of technology with our third clinical program, as well as our first proof of mechanism in our UB-312 program for Parkinson’s.
  • Results from the Phase 2a trial of UB-311 in patients with mild AD were published in The Lancet’s eBioMedicine in August 2023.
  • General and administrative expenses were $5.5 million and $7.3 million for the three months ended September 30, 2023, and 2022, respectively.

LAPIX Therapeutics Inc. Announces First Subjects Dosed in its First-in-Human Clinical Study of its Treg-expanding Tim3/4 Agonist LPX-TI641 to Treat Multiple Sclerosis and other Autoimmune Conditions

Retrieved on: 
Tuesday, November 7, 2023
Immune tolerance, Autoimmunity, Multiple sclerosis, LPX, Rheumatoid arthritis, TIM, Volunteering, Pharmacokinetics, Immune system, Safety, Therapy, Patient, MS, Lupus, Pharmaceutical industry, Vaccine

LPX-TI641 is a novel, and proprietary first-in-class orally bioavailable small molecule designed as a T cell immunoglobulin and mucin domain-containing protein (Tim) 3/4 receptor agonist.

Key Points: 
  • LPX-TI641 is a novel, and proprietary first-in-class orally bioavailable small molecule designed as a T cell immunoglobulin and mucin domain-containing protein (Tim) 3/4 receptor agonist.
  • LPX-TI641 restores the balance of regulatory immune cells (T- and B-regs) to autoreactive T-cells reestablishing immune tolerance.
  • It is being developed for the treatment of Multiple Sclerosis (MS) and potentially other autoimmune diseases such as rheumatoid arthritis and lupus.
  • The study is a randomized, double-blind, placebo-controlled study in healthy adult volunteers to evaluate the safety, tolerability, and pharmacokinetics of LPX-TI641 after single ascending oral doses.

Selecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercialization Partner Sobi

Retrieved on: 
Tuesday, October 31, 2023
Immune tolerance, BLA, Biologics license application, Pharmaceutical industry, Selecta, Swedish Orphan Biovitrum

(Sobi).

Key Points: 
  • (Sobi).
  • As of November 6, 2023, Sobi will assume responsibility for the manufacturing and commercial supply of ImmTOR for SEL-212.
  • In connection with this transition, 15 Selecta employees currently supporting ImmTOR manufacturing and clinical development activities for SEL-212 are expected to become employees of Sobi.
  • Selecta is eligible to receive up to $615.0 million in remaining regulatory and commercial milestone payments and tiered double-digit royalties on net sales of SEL-212.